A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: Establishment of normal levels and clinical application in patients with inflammatory bowel disease

被引:0
|
作者
Peterson, CGB [1 ]
Eklund, E
Taha, Y
Raab, Y
Carlson, M
机构
[1] Pharmacia Diagnost AB, Gastrointestinal Res, R&D, SE-75182 Uppsala, Sweden
[2] Univ Hosp, Dept Med Sci, Inflammat Res Lab, Uppsala, Sweden
[3] Univ Hosp, Dept Surg, Uppsala, Sweden
来源
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2002年 / 97卷 / 07期
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVES: The aims of this study were 1) to develop a valid method for the measurement of the eosinophil proteins eosinophil cationic protein (ECP) and eosinophil protein X (EPX) and neutrophil proteins myeloperoxidase and human neutrophil lipocalin (HNL) in feces and 2) to investigate their potential role as disease activity markers in inflammatory bowel disease (IBD). METHODS: Feces samples were obtained from 44 apparently healthy individuals (HIs), 18 patients with IBD (11 with ulcerative colitis [UC] and seven with Crohn's disease [CD]), and three with collagen colitis. The granulocyte markers were measured using immunoassays in supernatants from processed feces. RESULTS: ECP, myeloperoxidase, and, to a lesser degree, EPX and HNL were bound to the solid part of feces. However, feces homogenized in an extraction buffer containing the cationic detergent N-cetyl-N,N,N-trimethylammonium bromide allowed an efficient recovery of the proteins (i.e., up to 100-fold increased levels compared to homogenization in saline). All four proteins were stable for at least 7 days at +6degreesC and at least 3 days at +22degreesC. The normal fecal geometric mean (95th percentile) levels of ECP, EPX, myeloperoxidase, and HNL were estimated to be, respectively, 1.69 mug/g (6.41), 0.57 mug/g (1.72), 3.54 mug/g (8.77), and 1.97 mug/g (4.91). Markedly increased feces levels of all markers (p < 0.0002), compared to HIs and CD patients, were observed in UC. However, the marker levels in CID patients were significantly increased relative to HIs (1) < 0.05 to p < 0.0002). Increased levels of HNL and myeloperoxidase were also observed in the three collagen colitis patients. The discriminative capability between UC patients and HIs was somewhat superior for EPX and myeloperoxidase. CONCLUSIONS: The method described here takes into account the molecular proper-ties of the granule proteins and the heterogeneity in feces consistency, which is a prerequisite for a valid and reproducible measurement of cationic granule proteins. We suggest that EPX and myeloperoxidase, when applied in IBD, are the best eosinophil and neutrophil markers for studying GI inflammation.
引用
收藏
页码:1755 / 1762
页数:8
相关论文
共 50 条
  • [31] Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease
    Choi, So Yoon
    Kang, Ben
    Lee, Jee Hyun
    Choe, Yon Ho
    GUT AND LIVER, 2017, 11 (01) : 55 - 61
  • [32] Clinical utility of calprotectin and lactoferrin in patients with inflammatory bowel disease: is there something new from the literature?
    Caccaro, Roberta
    D'Inca, Renata
    Pathak, Surajit
    Sturniolo, Giacomo Carlo
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2012, 8 (06) : 579 - 585
  • [33] DEVELOPMENT AND VALIDATION OF NEW CLINICAL DISEASE SEVERITY INDEX FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE MULTICENTRE STUDY
    Alrubaiy, L.
    GUT, 2013, 62 : A34 - A34
  • [34] Clinical Relevance of CD-68 Positive Cells in Normal Buccal Mucosa in Patients with Inflammatory Bowel Disease
    Sincic, Brankica Mijandrusic
    Tomas, Maja Ilic
    Gobic, Margita Belusic
    Juretic, Mirna
    Kovac, Drazen
    Lekic, Andrica
    Pugel, Ester Pernjak
    Cerovic, Robert
    Stimac, Davor
    CROATICA CHEMICA ACTA, 2012, 85 (02) : 171 - 176
  • [35] Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice
    Aguas Peris, Mariam
    Boso, Virginia
    Navarro, Belen
    Marques-Minana, Maria R.
    Bastida, Guillermo
    Beltran, Belen
    Iborra, Marisa
    Saez-Gonzalez, Esteban
    Monte-Boquet, Emilio
    Poveda-Andres, Jose L.
    Nos, Pilar
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (08) : 454 - 460
  • [36] Week 2 Adalimumab Levels Predict Short-term Clinical Remission in Patients With Inflammatory Bowel Disease
    Buffone, Elisa
    Gupta, Shaan
    Al Ibrahim, Bashaar
    Marshall, John K.
    Halder, Smita
    Tse, Frances
    Albashir, Siwar
    Morgan, David
    Lumb, Barry
    Armstrong, David
    Narula, Neeraj
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2022, 56 (09) : 794 - 797
  • [37] Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Levels in Patients with Inflammatory Bowel Disease
    Afif, Waqqas
    Loftus, Edward V.
    Faubion, William A.
    Hanson, Karen A.
    Sandborn, William J.
    GASTROENTEROLOGY, 2009, 136 (05) : A147 - A147
  • [38] Thiopurine methyltransferase activity is correlated with azathioprine metabolite levels in inflammatory bowel disease patients in clinical gastroenterology practice
    Bloomfeld, RS
    Bickston, SJ
    Levine, ME
    Carroll, SM
    Smith, K
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10): : S255 - S255
  • [39] Adalimumab Trough Levels and Response to Biological Treatment in Patients With Inflammatory Bowel Disease: A Useful Cutoff in Clinical Practice
    Bodini, Giorgia
    Giannini, Edoardo G.
    Savarino, Edoardo V.
    Savarino, Vincenzo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 (03): : 472 - 473
  • [40] Clinical Implications of Measuring Infliximab Levels and Human Anti-Chimeric Antibodies in Patients with Inflammatory Bowel Disease
    Rai, Tarun
    Navaneethan, Udayakumar
    Dalal, Deepan
    Lashner, Bret
    Shen, Bo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S634 - S634